Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C.
Lin
Yong Q
YQ
Division of Endocrinology, Saint Peter's University Hospital, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, USA.
Wang
Xiangbing
X
Murthy
Meena S
MS
Agarwala
Sumon
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D013956:Antithyroid Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance; D011092:Polyethylene Glycols; D011433:Propranolol / Q000627:therapeutic use; D011441:Propylthiouracil / Q000627:therapeutic use; D011994:Recombinant Proteins; D019233:Retreatment; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index; D013971:Thyrotoxicosis / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology
D000319:Adrenergic beta-Antagonists; D013956:Antithyroid Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D011441:Propylthiouracil; D011433:Propranolol; C417083:peginterferon alfa-2b